Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Current Assets (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Current Assets for 10 consecutive years, with $225.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets rose 126.38% year-over-year to $225.1 million, compared with a TTM value of $225.1 million through Sep 2025, up 126.38%, and an annual FY2024 reading of $86.0 million, down 1.05% over the prior year.
  • Current Assets was $225.1 million for Q3 2025 at Zevra Therapeutics, down from $226.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $226.3 million in Q2 2025 and bottomed at $60.9 million in Q2 2024.
  • Average Current Assets over 5 years is $111.5 million, with a median of $99.4 million recorded in 2024.
  • The sharpest move saw Current Assets soared 1553.12% in 2021, then plummeted 41.13% in 2024.
  • Year by year, Current Assets stood at $115.1 million in 2021, then fell by 19.31% to $92.8 million in 2022, then decreased by 6.35% to $86.9 million in 2023, then dropped by 1.05% to $86.0 million in 2024, then soared by 161.68% to $225.1 million in 2025.
  • Business Quant data shows Current Assets for ZVRA at $225.1 million in Q3 2025, $226.3 million in Q2 2025, and $81.6 million in Q1 2025.